Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis by Bruijn, M.J.W. (Marjolein) de et al.
ARTICLE OPEN ACCESS
Evaluation of seizure treatment in anti-LGI1,
anti-NMDAR, and anti-GABABR encephalitis
Marienke A.A.M. de Bruijn, MD, Agnes van Sonderen, MD, PhD,
Marleen H. van Coevorden-Hameete, MD, PhD, Anna E.M. Bastiaansen, MD, Marco W.J. Schreurs, PhD,
Rob P.W. Rouhl, MD, PhD, Cees A. van Donselaar, MD, PhD, Marian H.J.M. Majoie, MD, PhD,
Rinze F. Neuteboom, MD, PhD, Peter A.E. Sillevis Smitt, MD, PhD, Roland D. Thijs, MD, PhD, and
Maarten J. Titulaer, MD, PhD
Neurology® 2019;92:e2185-e2196. doi:10.1212/WNL.0000000000007475
Correspondence
Dr. Titulaer
m.titulaer@erasmusmc.nl
Abstract
Objective
This nationwide cohort study evaluates seizure responses to immunotherapy and antiepileptic
drugs (AEDs) in patients with anti-leucine-rich glioma-inactivated 1 (LGI1), anti-NMDA
receptor (NMDAR), and anti-gamma-aminobutyric-acid B receptor (GABABR) encephalitis.
Methods
Anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis patients with new-onset seizures
were included. Medical information about disease course, AEDs and immunotherapies used,
eﬀects, and side eﬀects were collected. Outcomemeasures were (1) seizure freedomwhile using
AEDs or immunotherapy, (2) days to seizure freedom from start of AEDs or immunotherapy,
and (3) side eﬀects.
Results
Of 153 patients with autoimmune encephalitis (AIE) (53 LGI1, 75 NMDAR, 25 GABABR),
72% (n = 110) had epileptic seizures, and 89% reached seizure freedom. At least 53% achieved
seizure freedom shortly after immunotherapy, and 14% achieved seizure freedom while using
only AEDs (p < 0.0001). This eﬀect was similar in all types (p = 0.0001; p = 0.0005; p = 0.013,
respectively). Median time to seizure freedom from AEDs start was 59 days (interquartile range
[IQR] 27–160), and 28 days from start of immunotherapy (IQR 9–71, p < 0.0001). Side eﬀects
were psychotic behavior and suicidal thoughts by the use of levetiracetam, and rash by the use of
carbamazepine. Carbamazepine was more eﬀective than levetiracetam in reducing seizures in
anti-LGI1 encephalitis (p = 0.031). Only 1 patient, of 86 surviving patients, developed epilepsy
after resolved encephalitis.
Conclusion
Epilepsy after resolved encephalitis was rare in our cohort of patients with AIE treated with
immunotherapy. In addition, seizure freedom is achieved faster and more frequently after
immunotherapy. Therefore, AEDs should be considered as add-on treatment, and similar to
treatment of other encephalitis symptoms, immunotherapy is crucial.
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The discovery of NMDA receptor (NMDAR) antibodies1 has
led to the description of several other antibodies to extracel-
lular neuronal antigens. Binding of these antibodies leads to
cerebral dysfunction, which often manifests as limbic encepha-
litis characterized by cognitive decline, behavioral changes, and
seizures. Seizures occur most frequently in autoimmune en-
cephalitis (AIE) with leucine-rich glioma-inactivated 1 (LGI1),2
NMDAR antibodies,3 and gamma-aminobutyric-acid B receptor
(GABABR) antibodies.
4
The description of seizures in AIE has led to a new ﬁeld of
interest in epileptology with challenging issues in diagnosis
and treatment. Concerning diagnosis, patients can present
with seizures without other notable encephalitis signs,5–7
leading to diagnostic diﬃculties and treatment delay. Treat-
ment delay is associated with a poorer outcome.3 Therefore, it
is essential to consider an autoimmune etiology in presence of
speciﬁc clinical clues. Moreover, faciobrachial dystonic seizures
(FBDS)2 are considered pathognomonic for anti-LGI1 en-
cephalitis. Alternatively, the subacute onset of drug-resistant
seizures might be a common, but indiscriminative, feature.
Another challenging issue is to achieve seizure freedom rap-
idly. Seizures often seem unresponsive to antiepileptic drugs
(AEDs), while responses to immunotherapy are considered
good. Nevertheless, seizure freedom is not always achieved
while using immunotherapy alone and AEDs are sometimes
needed as well.
The overall eﬃcacy of AEDs in these patients and whether
any particular AEDs should be preferred is unclear. Therefore,
the aim of this nationwide observational cohort study was to
evaluate the responses to AEDs and immunotherapy in these
syndromes, including safety, and to describe the risk for epi-
lepsy after resolved encephalitis.
Methods
Patients
The department of neurology of the Erasmus MC University
Medical Center is the national referral site for patients with
suspected AIE and the department of immunology is the
national referral site for antineuronal antibody testing. We
identiﬁed all Dutch adults and children with AIE with LGI1,
NMDAR, or GABABR antibodies. Patients were identiﬁed
between August 1999 and May 2017, although 78% were
identiﬁed after 2010. Antibodies were detected in serum or in
CSF and conﬁrmed with both cell-based assay and
immunohistochemistry.8 Patients with new-onset seizures
during their active disease course were included.
Standard protocol approvals, registrations,
and patient consents
The medical ethics committee of the Erasmus MC University
Medical Center approved this study. Written informed con-
sent was obtained from all patients.
Seizures
Medical information about disease course, seizure type, status
epilepticus, types of AEDs and immunotherapies used, and
side eﬀects of the diﬀerent treatments were collected during
a visit to our clinic (n = 77), from interviews with patients and
relatives by phone (n = 27), and from medical ﬁles (n = 49).
Clinical characteristics, including all encephalitis signs, of
a part of the patients have been published before.9,10 To
provide an overview of the clinical signs, we allocated patients
into 2 groups: epileptic seizures plus and encephalitis. No
patients had only epileptic seizures without any other neu-
rologic symptoms at thorough examination. Epileptic seizures
plus contained the patients with prominent seizures and only
subtle other encephalitis signs, which were initially un-
recognized or considered side eﬀects of AEDs. Examples are
mild cognitive complaints, behavioral disorders, or subtle
movement disorders. Limbic encephalitis was deﬁned as an
encephalitis with predominant clinical involvement of the
limbic system (short-term memory loss, diﬃculty forming
new memories, behavioral disorder) or MRI ﬂuid-attenuated
inversion recovery/T2 abnormalities in the medial temporal
lobes.11
The guidelines and new epilepsy classiﬁcation of the In-
ternational League Against Epilepsy (ILAE) were used to
deﬁne epileptic seizures,12 epileptic seizures with an immune
etiology,13 status epilepticus,14 and drug-resistant epileptic
seizures,15 and to classify seizures.12,13,16 Epileptic seizures
with an immune etiology were deﬁned as at least 2 seizures,
not provoked by other factors, occurring more than 24 hours
apart resulting directly from an immune disorder, and with
evidence of autoimmune-mediated CNS inﬂammation.12,16
Drug-resistant epileptic seizures were deﬁned as failure to
achieve seizure freedom, despite treatment with 2 tolerated,
adequately dosed AEDs. Seizures were classiﬁed as focal or
tonic–clonic. Moreover, focal seizures were classiﬁed as seiz-
ures with or without impaired awareness. FBDS were deﬁned
as frequent attacks (>8/d) with a dystonic posture of the arm,
often combined with a facial contraction, lasting less than 30
seconds.2 Refractory status epilepticus was deﬁned as status
Glossary
AED = antiepileptic drug; AIE = autoimmune encephalitis; FBDS = faciobrachial dystonic seizures; GABABR = gamma-
aminobutyric acid B-receptor; GAD65 = glutamic acid decarboxylase 65; HLA = human leukocyte antigen; ILAE =
International League Against Epilepsy; IQR = interquartile range; LGI1 = leucine-rich glioma-inactivated 1; mRS = modiﬁed
Rankin Scale; NMDAR = NMDA receptor; VGKC = voltage-gated potassium channel.
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epilepticus continuing even after adequate treatment. Seizure
freedom was deﬁned as no clinical signs of seizures, meaning
no seizures observed and no reporting of focal seizures (in-
cluding auras) or tonic-clonic seizures by patients or physi-
cians. At follow-up, seizures needed to be absent for at least
3 months.
Eﬀectivity of AEDs was scored as ineﬀective, some eﬀect,
seizure freedom, or unknown eﬀect. As this was no formal
prospective study, some eﬀects were diﬃcult to assess pre-
cisely, and we could therefore not use frequently used varia-
bles like 50% seizure reduction. We only scored some eﬀect
when it was noted speciﬁcally as a considerable reduction.
Level of functioning was measured with the modiﬁed Rankin
Scale (mRS).17
Primary outcome measures were (1) seizure freedom ach-
ieved while using AEDs and while using immunotherapy, (2)
days to seizure freedom from start of AEDs and from start of
immunotherapy, (3) development of epilepsy after resolved
encephalitis, and (4) reported side eﬀects.
Statistics
Comparisons between 2 groups were performed with the
Mann-Whitney U test (days to seizure freedom after start of
epileptic seizures). Comparisons between multiple groups
were performed with the Kruskal-Wallis test (age at onset,
days to seizures after disease onset), the Fisher-Freeman-
Halton test (comparing eﬀects of diﬀerent AEDs), and the
one-way analysis of variance (sex, seizures presenting symp-
tom, type of seizures at presentation and during disease
course, and [refractory] status epilepticus).
The chances to achieve seizure freedom (during ﬁrst disease
episode) were compared by McNemar test, only in patients
using both AED and immunotherapy before seizure freedom
to avoid confounding by indication. For each patient in-
dividually, achievement of seizure freedom after the diﬀerent
treatments is shown visually in the ﬁgures. McNemar test
was also used to compare AED treatment responses in
patients receiving multiple AEDs. The Wilcoxon signed
rank test was used to compare the days to seizure freedom
from start of AEDs and from start of immunotherapy. For
this test only responses of patients who were treated with
both AEDs and immunotherapy before seizure freedom
were evaluated.
p Values below 0.05 were considered signiﬁcant. We used
SPSS 21.0 (SPSS Inc., Chicago, IL) for Windows and Prism7
(GraphPad Software, La Jolla, CA) for Windows for statistical
analysis.
Data availability statement
Any data not published within this article are available at the
Erasmus MC University Medical Center. Patient-related data
will be shared upon request from any qualiﬁed investigator,
maintaining anonymization of the individual patients.
Results
Patient and seizure characteristics
We identiﬁed 153 patients with AIE, including 53 patients
with LGI1 antibodies, 75 patients with NMDAR antibodies,
and 25 patients with GABABR antibodies. Among these cases,
72% of patients (n = 110) had epileptic seizures with an
immune origin (87% LGI1, 57% NMDAR, 84% GABABR),
while 14 additional patients (9%) had only one seizure.
Table 1 shows seizure characteristics per antibody. Patients
with NMDAR antibodies were younger (p < 0.0001) and only
in this group there was a female predominance (p < 0.0001).
Fourteen patients were categorized as having epileptic seiz-
ures plus (10/46 [22%] with LGI1 antibodies, 4/43 [9%]
with NMDAR antibodies, and 0/21 with GABABR anti-
bodies); the others had limbic encephalitis or panencephalitis.
FBDS only occurred in patients with LGI1 antibodies (53%).
All patients with GABABR antibodies had tonic-clonic seiz-
ures, compared to 55% of patients with LGI1 antibodies (p =
0.0002), and 79% of patients with NMDAR antibodies. Status
epilepticus occurred frequently (n = 38, 34%), in particular in
patients with GABABR antibodies (62%, p = 0.006), of whom
26 (68%) had a refractory status epilepticus. Five patients
(4%) died during status epilepticus.
Median follow-up time from onset of seizures was 27 months
(interquartile range [IQR] 15–49, range 0–149 months); 24
patients had died (22%). Twenty-ﬁve patients (23%) had
a relapse of the encephalitis; among them, 76% again had
seizures (10 LGI1, 5 NMDAR, 4 GABABR). At last follow-up,
66% of patients had an mRS of 0–2 (LGI1 78%, NMDAR
74%, GABABR 24%).
Seizure treatment
Of all 110 patients with new-onset epileptic seizures with an
immune origin, 91%were treated with 1 or more AEDs (LGI1
80%, NMDAR 98%, GABABR 100%). The median delay
between seizure onset and start of AEDswas 3 days (IQR 0–31).
This delay was higher in patients with anti-LGI1 encephalitis
(median 64 days, IQR 0–178, p < 0.0001). During their disease
course, patients were treatedwith amedian of 2AEDs (IQR1–3,
range 0–9). Moreover, 71 patients (65%) were treated with 2 or
more AEDs. AEDs were continued for a median period of 8
months after diagnosis (IQR 4–18, range 0–102 months).
Most patients were treated with immunotherapy (92%), all
but one with ﬁrst-line immunotherapy (combination of
methylprednisolone or IV immunoglobulins or plasmaphe-
resis), and 17% with additional second-line immunotherapy
(rituximab or cyclophosphamide; table 2). The patients not
treated with immunotherapy received only AEDs (n = 9).
Twenty-one percent of patients were treated with chronic
immunotherapy, including azathioprine (n = 15) or myco-
phenolate (n = 8); of them, 19 (83%) had LGI1 antibodies.
Fifteen of 19 anti-LGI1 patients were treated with chronic
immunotherapy after the initial episode. Two of these anti-
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LGI1 patients (13%) developed a relapse, necessitating
adaptation of the chronic immunotherapy. Thirty-one anti-
LGI1 patients did not receive chronic immunotherapy after
the initial episode. Of these, 11 developed a relapse (35%).
Four patients had only started chronic immunotherapy after
relapse. One of these 4 patients developed multiple relapses
that halted after administration of rituximab.
The majority of patients with anti-NMDAR and anti-
GABABR encephalitis were treated with both AEDs and
immunotherapy (NMDAR 93%, GABABR 81%). This per-
centage tended to be lower in patients with anti-LGI1 en-
cephalitis (71%, p = 0.051). Among anti-LGI1 encephalitis
patients, more were treated with immunotherapy (91%) than
with AEDs (80%). The median treatment delay between
symptom onset and start of immunotherapy was 30 days
(IQR 11–93), which was highest in the anti-LGI1 group
(median of 96 days, IQR 48–290, p < 0.0001). Patients with
anti-LGI1 encephalitis and focal seizures had a longer treat-
ment delay (p = 0.007) than patients without focal seizures,
while this delay was not observed in patients with anti-LGI1
encephalitis and FBDS (p = 0.20).
Seizure freedom and treatment effects
Figures 1–3 visualize timelines of all patients with epileptic
seizures per antibody. Seizure freedom was achieved in 89% of all
110 patients. Of these 98 patients, 14% (n = 14) achieved seizure
freedom while using only AEDs, while in 52 patients seizure
Table 1 Patient and seizure characteristics
LGI1 (n = 46/53) NMDAR (n = 43/75) GABABR (n = 21/25) p Value
Male 30 (65) 7 (16) 10 (48) <0.0001
Tumora 3 (7) 10 (23) 14 (67) <0.0001
Median age at onset, y 65 (58–69, 9–84) 20 (16–30, 3–73) 64 (56–75, 43–78) <0.0001
Median days to seizures after disease onset 0 (0–31, 0–365) 0 (0–14, 0–151) 0 (0–3, 0–37) 0.31
Seizures presenting symptom 28 (61) 21 (48) 16 (76) 0.11
Type of seizures at presentation
Focal seizures 22 (48) 13 (33) 5 (24) 0.10
Faciobrachial dystonic seizures 15 (32) 0 0 <0.0001
Tonic-clonic seizures 9 (20) 29 (67) 16 (76) <0.0001
Type of seizures during disease course
Focal seizures 39 (83) 32 (74) 8 (38) 0.0001
With impaired awareness 28 (72) 14 (42) 7 (88) 0.033
Without impaired awareness 15 (38) 18 (55) 1 (13) 0.033
Motor 0 17 (51) 0
Autonomic 10 (26) 0 0
Sensory 3 (8) 1 (3) 0
Cognitive 1 (3) 0 1 (13)
Emotional 1 (3) 0 0
FBDS 25 (53) 0 0
Tonic-clonic seizures 26 (55) 34 (79) 21 (100) 0.0002
Status epilepticus 10 (22) 15 (35) 13 (62) 0.006
Refractory status epilepticus 7/46 (15) 9/43 (21) 10/21 (48) 0.014
Relapses 14 (30) 6 (14) 5 (24) 0.18
Relapses with seizures 10/46 (22) 5/43 (12) 4/21 (19) 0.44
Abbreviations: FBDS = faciobrachial dystonic seizures; GABABR = gamma-aminobutyric acid B-receptor; LGI1 = leucine-rich glioma-inactivated 1; NMDAR =
NMDA receptor.
Values are n (%) or interquartile range (range).
a Tumors: Anti-LGI1 encephalitis: 1 patient had a thymoma, 1 patient amesothelioma, and 1 patient rectal carcinoma in situ (detected 2months before onset
of neurologic disease). Anti-NMDAR encephalitis: 8 patients had ovarian teratoma, 1 patient Merkel cell carcinoma, and 1 patient renal oncocytoma. Anti-
GABABR encephalitis: All 14 patients had a small cell lung carcinoma.
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Table 2 Overview of all patients treated with immunotherapy
Group Treatmenta No. of patients %
LGI1 (n = 42/46) Oral prednisone only 7 17
IVMP only 3 7
IVMP + oral prednisone 11 26
IVIg only 2 5
IVMP + IVIg 3 7
IVIg + oral prednisone 1 2
IVMP + IVIg + oral prednisone 12 29
IVMP + Plex + RTX 1 2
IVMP + IVIg + RTX 1 2
IVMP + IVIg + oral prednisone + RTX 1 2
Suggested treatment (since early 2015): IVMP (5 d 1,000 mg) + IVIg (5 d, 0.4 g/kg) + prednisone (start 60 mg/d) + azathioprine 2 × 75 mg/d). If
insufficient, RTX might be added.
70
NMDAR (n = 41/43) IVMP only 7 (2 OT and resection) 17
IVMP + oral prednisone 2 5
IVMP + IVIg 11 (3 OT and resection) 27
IVMP + IVIg + oral prednisone 5 12
IVMP + IVIg + Plex 3 7
IVIg + oral steroids + Plex 1 2
IVIg + RTX 1 2
IVMP + IVIg + RTX 2 5
IVMP + oral prednisone + IVIg + RTX 1 2
IVMP + Plex + RTX 1 (1 OT and resection) 2
IVMP + IVIg + Plex + RTX 1 2
IVMP + IVIg + RTX + Cyclo 6 (2 OT and resection) 15
Suggested treatment (since early 2014): IVMP (5 d, 1,000 mg) + IVIg (5 d, 0.4 g/kg)
If effective, IVMP is repeated after 4 and 8 wk
If ineffective, second-line immunotherapy RTX (1,000mg, 2 courses, 14 d apart + Cyclo (15mg/kg, 3 courses, 14 d apart, continued 500mg/14
d or 1,000 mg/28 d). In children, RTX only is preferred
79
GABABR (n = 18/21) IVMP only 4 (1 SCLC, chemo) 22
IVMP + oral prednisone 3 (1 SCLC, chemo) 17
IVMP + IVIg 5 (4 SCLC, chemo [n = 4], radiation [n = 2], resection [n = 1]) 28
IVMP + IVIg + oral prednisone 4 (1 SCLC, chemo) 22
RTX 1 (1 SCLC, chemo) 6
IVMP + IVIg + Cyclo 1 6
Suggested treatment (since early 2014): IVMP (5 d, 1,000mg) + IVIg (5 d, 0.4 g/kg). Treatmentafter hyperacutephasedepends on improvement
and tumor status. Options: IVMP repetition after 4 and 8 wk (3 d, 1,000 mg), or second-line immunotherapy can be considered (see anti-
NMDAR) if improvement is mediocre.
70
Abbreviations: Cyclo = cyclophosphamide; GABABR = gamma-aminobutyric acid B-receptor; IVIg = IV immunoglobulins; IVMP = IVmethylprednisolone; LGI1 =
leucine-rich glioma-inactivated 1; NMDAR=NMDA receptor; OT = ovarian teratoma; Plex = plasmapheresis; RTX = rituximab; SCLC = small cell lung carcinoma.
a Tumor therapy in addition to immunotherapy when a tumor is found.
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freedom was achieved shortly after the start of immunotherapy
(53%). Comparing the 68 patients receiving both AEDs and
immunotherapy before seizure freedom was reached, the chance
to achieve seizure freedom was higher after the use of immuno-
therapy than after the use ofAEDs (immunotherapy n= 44, AEDs
n = 3, p < 0.0001). This also applied for the groups separately
(LGI1, p = 0.0001; NMDAR, p = 0.0005; GABABR, p = 0.013).
The median time to achieve seizure freedom after the start of
AEDs was 59 days (IQR 27–160), and 28 days from start of
immunotherapy (IQR 9–71, p < 0.0001). This decrease in
days to seizure freedom after the use of immunotherapy
was observed in all 3 syndromes (LGI1, p < 0.0001; NMDAR,
p < 0.0001; GABABR, p = 0.001).
Seizure freedom was achieved faster in women than in men
(p < 0.0001), attributed to patients with anti-NMDAR
encephalitis (p = 0.038). No diﬀerences were observed in days
to seizure freedom between patients with paraneoplastic18 (n
= 27) or nonparaneoplastic encephalitis (n = 83; p = 0.085).
In patients with focal seizures, it took longer to achieve seizure
freedom (p < 0.0001), while presence of tonic-clonic seizures
did not inﬂuence the interval to seizure freedom (p = 0.081).
In patients with LGI1 antibodies, the presence of FBDS did
not shorten the interval to seizure freedom (p = 0.20).
Eleven patients did not reach seizure freedom. Ten patients
had died, due to the encephalitis, before reaching seizure
freedom, while one patient with anti-LGI1 encephalitis (3%
of surviving patients with seizures and anti-LGI1 enceph-
alitis) developed temporal epilepsy after resolved enceph-
alitis. Median time of seizure freedom in AIE patients (after
initial episode or last relapse) was 22 months (IQR 14–45,
range 4–129). Fourteen of these patients (14%) were still
Figure 1 Timelines (in days) of anti–leucine-rich glioma-inactivated 1 encephalitis patients with epileptic seizures
The percentages shown on the left correspond to patients (1) reaching seizure freedom after the use of immunotherapy (green), (2) reaching seizure freedom
probably after the use of immunotherapy (triple green), (3) reaching seizure freedom after the use of antiepileptic drugs (AEDs) (red), (4) reaching seizure
freedom probably after the use of AEDs (double red), (5) who could not be categorized (gray stripes), and (6) who did not reach seizure freedom (black dots). If
patientswere treatedwith another immunomodulating treatment >1month after the initial treatment (for example, IV immunoglobulin after prednisolone), this
is shown as a new blue square. Treatment with an additional AED or dosage increase after >1 month is shown as a second purple diamond. Relapses are only
shown if patients had seizures. Median time of follow-up from onset was 33 months (interquartile range [IQR] 19–52, range 8–119). Median time of seizure
freedomwas 23months (IQR14–40, range 4–102). Themedian interval between start of AEDs and start of immunotherapywas 57days (IQR27–152). **Timeline
of the only patient who developed epilepsy after resolved encephalitis. The symbols in this timeline are not fitted to scale. The onset of seizures was in 2009, the
patient was treated with prednisone (and AEDs), leading to reversibility of cognitive signs, but he still has temporal epilepsy. IT = immunotherapy.
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using AED, while seizure-free. We have evaluated the pro-
portion of patients who continued to have seizures at 6, 12,
and 24 months after the initiation of immunotherapy
(ﬁgure 4). At 6 months, seizure freedom was achieved in
79% of patients; of these 73 patients, 38 (52%) still used
AEDs. At 12 months, 96% of patients had reached seizure
freedom, of whom 34% still used AEDs while seizure-free.
At 24 months, only one patient had developed epilepsy
after resolved encephalitis (2%); the other 46 patients
(98%) were seizure-free, among them 4 (9%) treated with
AEDs. Fourteen patients developed a relapse with epileptic
seizures within these 2 years (7 while using AED), and 12
became seizure-free again within days or weeks after
restarting immunotherapy.
AED effects and side effects
Prescribed AEDs were levetiracetam (66%), valproic acid
(53%), carbamazepine (32%), phenytoin (30%), clobazam
(15%), lacosamide (7%), oxcarbazepine (6%), and lamo-
trigine (5%). Topiramate and phenobarbital were only used
sporadically.
Responses to these most prescribed AEDs and side eﬀects are
visualized in ﬁgure 5. Although some response was seen in all
3 groups, seizure freedom was only infrequently achieved.
Carbamazepine appeared to have the best eﬀect to reduce
focal seizure frequency in anti-LGI1 encephalitis (ﬁgure
5D), while FBDS hardly responded to AEDs (ﬁgure 5E). In
those anti-LGI1 patients treated with both levetiracetam
and carbamazepine (n = 15), carbamazepine appeared
more eﬀective to reduce seizure frequency than levetir-
acetam (p = 0.031).
Side eﬀects were frequently reported by patients with anti-
LGI1 encephalitis (37%), and less by patients with anti-NMDAR
(18%) and anti-GABABR (15%) encephalitis. Patients with
LGI1 antibodies frequently had a rash by the use of carbama-
zepine (7/22, 32%). Most reported side eﬀects by the use of
valproic acid were memory deterioration (n = 3) and tremor
(n = 2). Side eﬀects of levetiracetam were rash (n = 3) and
serious behavioral changes (n = 14; 19%), including 2 patients
with anti-LGI1 encephalitis with severe psychotic behavior and
suicidal thoughts.
Figure 2 Timelines (in days) of anti–NMDA receptor encephalitis patients with epileptic seizures
See legend of figure 1. Median time of follow-up was 37 months (interquartile range [IQR] 15–59, range 1–149). Median time of seizure freedom was 31
months (IQR 15–58, range 4–129). The median interval between start of antiepileptic drugs (AEDs) and start of immunotherapy was 14 days (IQR 4–24). IT =
immunotherapy.
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Discussion
This nationwide observational cohort study evaluates seizure
responses to immunotherapy and AEDs in patients with anti-
LGI1, anti-NMDAR, and anti-GABABR encephalitis. We
show that seizure freedom is achieved faster and more fre-
quently after the use of immunotherapy than after the use of
AEDs. In some patients, AEDs might decrease seizure fre-
quency or lead to seizure freedom, but the eﬀect is limited and
incomparable to the eﬀect of immunotherapy. After immu-
notherapy, the development of epilepsy after resolved en-
cephalitis is rare in our cohort of AIE patients treated with
immunotherapy.
These results emphasize the usefulness of immunotherapy in
the treatment of epileptic seizures with an immune etiology
caused by extracellular neuronal antibodies. In all groups there
was a clear decrease in days to seizure freedom after the use of
immunotherapy. It is customary to start AEDs before
immunotherapy, so only comparing intervals between start of
diﬀerent treatments and seizure freedom would not be en-
tirely fair. To avoid this confounding, we in addition com-
pared the eﬀects of AEDs and immunotherapy in patients
who used both, and in which the responses to the individual
treatment could be determined. This showed a clear prefer-
ence for immunotherapy, which is in line with prior research
in anti-LGI1 encephalitis, showing the positive eﬀects of early
immunotherapy on epileptic seizures and cognition.5,19
The eﬀects of diﬀerent treatment options were visualized
(ﬁgures 1–3), showing that seizure freedom was frequently
preceded directly by the initiation of immunotherapy and that
patients treated earlier on in disease course seemed to reach
seizure freedom faster. This eﬀect was most remarkable in
patients with anti-LGI1 encephalitis, wherein almost half of
the patients became seizure-free within a week after immu-
notherapy, while they had been refractory to AEDs for longer
periods. We did not analyze the eﬀects of tumor treatment
Figure 3 Timelines (in days) of anti–gamma-aminobutyric acid B-receptor encephalitis patients with epileptic seizures
See legend of figure 1.Median time of follow-upwas 15months (interquartile range [IQR] 9–21, range 0–109).Median time of seizure freedomwas 15months
(IQR 9–20, range 5–100). The median interval between start of antiepileptic drugs (AEDs) and start of immunotherapy was 10 days (IQR 7–28). IT =
immunotherapy.
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separately, because it was always accompanied by immuno-
therapy. Yet, we visualized that in patients with paraneoplastic
encephalitis, both tumor treatment and immunomodulation
often preceded seizure freedom. Mechanistically, both im-
munotherapy and tumor treatment are causal treatments,
while AEDs are symptomatic treatments.
Our study shows that seizures of most patients were AED-
resistant. Seizure freedom was achieved in the minority of
patients while using only AEDs, and adjustments in treatment
regimen or dosage increase of AEDs did not aﬀect the chance
to achieve seizure freedom. In addition, these patients often
had a milder disease course without status epilepticus. The
AED-resistant character of seizures is a conﬁrmation of
observations in other studies.6,19,20 In addition, the often ac-
companying (subtle) cognitive symptoms also favor treat-
ment with immunotherapy. Therefore, it seems better to use
AEDs only as add-on symptomatic treatment.
After treating the acute phase of the encephalitis, the con-
tinued use of AEDs is debatable. In our study, AED therapy
was successfully discontinued in most patients after resolution
of encephalitis. Chronic AED use does not appear to be
necessary in most AIE patients long term. This is in line with
previous studies studying separate subtypes of AIE.5,9,20 Al-
though mesiotemporal sclerosis has been described in
25%–50% of follow-up MRIs in patients with anti-LGI1 en-
cephalitis, only a few develop epilepsy after resolved
encephalitis.9,21 For this reason, some argue against the
implementation of the term epilepsy with immune origin13
(new ILAE classiﬁcation) in the acute phase, reserving this for
the situation after the encephalitis has been treated.22 In
addition, side eﬀects of AEDs, like memory disturbances,
might disturb recovery after AIE, especially in combination
with other drugs inﬂuencing brain functions, questioning even
more the necessity for long-term AED use. Finally, half the
patients who experienced a clinical relapse with epileptic
seizures developed this relapse despite using AEDs and al-
most all patients became seizure-free again within days or
weeks after restarting immunotherapy. However, prospective
studies comparing diﬀerent treatments in the chronic disease
phase are lacking.
The AED-resistant character of seizures and crucial role of
immunotherapy in treatment of seizures stress the importance
of considering AIE as cause of epileptic seizures in patients
with acquired drug-resistant seizures. Due to increased
awareness, patients with a fulminant disease course with coma
and status epilepticus, most frequently caused by GABABR or
NMDAR antibodies, are regularly diagnosed early on in dis-
ease course. On the other hand, almost a quarter of the
patients with anti-LGI1 encephalitis did not have a full-blown
encephalitis, but seizures with only subtle encephalitis signs,
which were often unrecognized by referring physicians. The
unrecognition leads to diagnostic and treatment delay.9 In our
study, this is reﬂected by (1) the longest treatment delay, (2)
the longest interval between start of AEDs and immunotherapy,
(3) a lower percentage of patients treated with AEDs, and (4)
the observation that the presence of focal seizures extends the
time to seizure freedom. As FBDS have gained much attention,
better recognition and earlier treatment are to be expected. A
longer delay until diagnosis and appropriate treatment in those
with focal seizures shows that we should also look beyond FBDS
to reduce delays and improve outcomes.
Figure 4 Evaluation of the patients at risk to develop epilepsy after resolved encephalitis at 6, 12, and 24 months after the
initiation of immunotherapy
The figure shows the cumulative percentages of the
patients who reached or did not reach seizure free-
dom and the use of antiepileptic drugs (AEDs).
Patients with a relapse less than 3months before the
time point at 6, 12, or 24 months, or with a relapse at
6, 12, or 24 months, are also shown in the figure.
Fourteen patients developed a relapse with epileptic
seizures within 24 months after the start of immu-
notherapy, in 7 of them despite continuous AED
treatment. At relapse, the median seizure duration
was 12 days (interquartile range [IQR] 4–29, range
3–92). Eleven of these 14 patients became seizure-
free within days or weeks after restarting immuno-
therapy, 2 patients became seizure-free after 3
months, and 1 patient developed epilepsy after re-
solved encephalitis.
Neurology.org/N Neurology | Volume 92, Number 19 | May 7, 2019 e2193
Concerning responses to most prescribed AEDs, in our co-
hort, physicians preferred the use of levetiracetam. However,
patients often had serious behavioral changes and 2 patients
with anti-LGI1 encephalitis developed a severe psychosis and
suicidal thoughts. In addition, levetiracetam might exaggerate
symptoms of AIE, especially behavioral disorders. Focal
seizures of anti-LGI1 patients responded relatively better to
carbamazepine, while FBDS hardly responded to any AED.
Only a few patients were treated with oxcarbazepine, a drug
with a comparable mechanism of action as carbamazepine.
Individual results of treatment with oxcarbazepine seem
promising and comparable to the eﬀect of carbamazepine, but
need conﬁrmation in larger patient groups. Lacosamide,
a similar drug, was only used infrequently and as add-on,
therefore assessment of the eﬀects was impossible. A recent
study describes that only 10% of patients with voltage-gated
potassium channel (VGKC) complex and glutamic acid
decarboxylase 65 (GAD65) antibodies reached seizure free-
dom by the use of speciﬁc AEDs.23 Carbamazepine, lacosa-
mide, and oxcarbazepine led most frequently to seizure-free
outcome, while levetiracetam was ineﬀective in all patients.
This is in line with our results, but diﬃcult to compare as not
all VGKC complex antibodies are pathogenic24 and as the
pathogenicity of anti-GAD65 is unclear (incomparable to the
pathogenicity of antibodies to extracellular antigens).25
Side eﬀects were reported most frequently by patients with
LGI1 antibodies, and less by the other patients, probably due
to a more fulminant disease course in patients with anti-
GABABR and anti-NMDAR encephalitis. One-third of
patients with LGI1 antibodies treated with carbamazepine
had a rash. Rash is a common side eﬀect of carbamazepine and
occurs most often in patients with speciﬁc proimmunogenic
human leukocyte antigen (HLA) types.26 Recently, a strong
correlation with speciﬁc HLA types (HLA DR7 and DRB4)
was found in patients with LGI1 antibodies.27,28 Yet these
types do not correspond to the HLA types of patients who are
prone to rash by the use of carbamazepine. An alternative
explanation for the high percentage of rash within the LGI1
group might be the rapid dosage increase because of frequent,
drug-resistant seizures.
Although this is the largest cohort, and a nationwide study,
regarding seizure responses to diﬀerent treatments in patients
with AIE and epileptic seizures, there are some limitations
associated with the retrospective design of this study.
Figure 5 Response percentages of most prescribed antiepileptic drugs (AEDs) and side effects
Response percentages of most prescribed AEDs and side effects in patients with (A) anti–gamma-aminobutyric acid B-receptor (GABABR), (B) anti–NMDA
receptor (NMDAR), or (C) anti–leucine-rich glioma-inactivated 1 (LGI1) encephalitis, (D) focal seizures in patients with anti-LGI1 encephalitis, and (E) facio-
brachial dystonic seizures (FBDS) in patients with anti-LGI1 encephalitis.“Some effect”was scored if noted specifically as a considerable reduction of seizures.
In some patients, responses to specific AEDs were not assessable, due to concomitant use of immunotherapy or missing data. *A total of 20/21 patients with
anti-GABABR encephalitis were treated with levetiracetam (LEV) (n = 16) or valproic acid (VPA) (n = 15), 11 patients were treated with both LEV and VPA.
Responses of 2 patients treatedwith LEVwere not assessable. **A total of 40/42 patientswith anti-NMDAR encephalitis were treatedwith LEV (n = 28), VPA (n =
24), or carbamazepine (CBZ) (n = 10); in 17 patients, these AEDs were combined. Responses of seizures of 2 patients treated with VPA, 7 patients treated with
LEV, and 4 patients treated with CBZ were not assessable. ***A total of 37 patients with anti-LGI1 encephalitis were treated with LEV (n = 29), VPA (n = 19), or
CBZ (n = 22); in 25 patients, combinations of these AEDs were used. Responses of seizures of 4 patients treated with VPA, 6 patients treated with LEV, and 1
patient treatedwith CBZwere not assessable. Comparing patients treatedwith both LEV and CBZ (most prescribed, n = 15), CBZwasmore effective (p = 0.031).
In the LGI1 group, only 4 patients were treated with oxcarbazepine, 1 patient reached seizure freedom, 1 patient showed some effect, and 2 had no effect.
Treatment responses of patients with anti-LGI1 encephalitis are also shown for focal seizures (D) and FBDS (E). FBDS hardly responded to VPA, LEV, or CBZ,
while focal seizures responded somewhat better to carbamazepine.
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Concerning data collection, eﬀects and side eﬀects were not
always accurately documented. Patients were treated with
a variety of AEDs and immunotherapies, and not per protocol,
so comparisons are more diﬃcult. However, the visualization
of individual data in timelines is convincing that the diﬀer-
ences between eﬀects of AEDs and immunotherapy are real.
We were not able to compare diﬀerent treatment regimens
(diﬀerent AEDs and immunotherapies) due to small group
sizes. Especially side eﬀects are diﬃcult to evaluate system-
atically in a retrospective design. Cognitive decline and be-
havioral disorders are hallmark symptoms of AIE, making it
more diﬃcult to categorize symptoms as disease progression
or side eﬀects of treatment. In addition, severe disease courses
with coma and long-term intensive care stay make a proper
evaluation of treatment eﬀects (and side eﬀects) diﬃcult.
Nevertheless, by treating these patients and by interviewing
most patients, relatives, and treating physicians, important
eﬀects and side eﬀects were still assessable and results from
this study may help to compose treatment recommendations.
We would suggest using AEDs with sodium channel blocking
properties (like carbamazepine or potentially oxcarbazepine)
as ﬁrst add-on next to immunotherapy in the symptomatic
treatment of patients with anti-LGI1 encephalitis and seizures
as it seems to have at least some eﬀect in reducing focal
seizures. However, due to the frequent occurrence of rash,
often leading to discontinuation of therapy, it is essential to be
cautious with rapid dosage increase. On the other hand, lev-
etiracetam seems not preferable in the treatment of autoim-
mune epileptic seizures as the eﬀects are limited and it can
induce or exaggerate serious behavioral disorders.
From this nationwide study, we can conclude that immuno-
therapy is most important in the treatment of epileptic
seizures in patients with anti-LGI1, anti-NMDAR, and anti-
GABABR encephalitis. The overall eﬀect of AEDs in the
symptomatic treatment of epilepsy in these patients is limited
and antibody-dependent. Speciﬁc AEDs should be considered
to use as add-on therapy to control seizures, but not as pri-
mary and long-term treatment.
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